Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice

BACKGROUND: Current anti-cancer therapeutic antibodies that are used in the clinic are predominantly humanized or fully human immunoglobulin G1 (IgG1). These antibodies bind with high affinity to the target antigen and are efficient in activating the immune system via IgG Fc receptors and/or complem...

Descripción completa

Detalles Bibliográficos
Autores principales: Braster, Rens, Grewal, Simran, Visser, Remco, Einarsdottir, Helga K., van Egmond, Marjolein, Vidarsson, Gestur, Bögels, Marijn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438146/
https://www.ncbi.nlm.nih.gov/pubmed/28542406
http://dx.doi.org/10.1371/journal.pone.0177736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438146/
https://www.ncbi.nlm.nih.gov/pubmed/28542406
http://dx.doi.org/10.1371/journal.pone.0177736

Ejemplares similares